Radiation Syndrome Acute and Chronic
1. Dr. Samatbek Turdaliev
2. Edasseri Valappil Akbar Fathima Nasreen
James Abhishikth
(1. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.
2. Students, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Background
Ionising radiation saves millions of lives each year through cancer therapy, interventional cardiology and diagnostic imaging, yet it remains one of the most rapid and devastating occupational toxins known. Acute radiation syndrome (ARS) can kill within 72 hours, while chronic radiation injury insidiously compromises skin, marrow, vasculature and viscera for decades. Updated epidemiological and mechanistic intelligence is therefore essential for clinicians who manage accidental exposures, occupational health surveillance or cancer survivorship.
Methods
A structured scoping review (January 2019 – December 2024) was undertaken using PubMed, EMBASE, Cochrane, WHO IRIS, REAC/TS registry and grey literature. Eligible studies described (i) epidemiology, pathophysiology or clinical features of acute or chronic radiation syndrome in humans; (ii) diagnostic or therapeutic advances; (iii) occupational, environmental or iatrogenic exposures 2019-2023. Global Burden of Disease (GBD) 2023 supplied mortality and disability estimates.
Results
Global incidence of medically significant ARS remains low (≈ 0.2 cases/million/year), yet 2.3 million cancer survivors live with chronic radiation injury. ARS follows a predictable four-phase trajectory: prodromal (minutes–hours), latent (hours–weeks), manifest (days–weeks) and recovery/death. At doses > 0.7 Gy bone-marrow syndrome predominates; > 10 Gy gastrointestinal syndrome; > 50 Gy cardiovascular/CNS syndrome with 100 % lethality within 72 h. High-resolution CT and 48-hour lymphocyte-depletion kinetics predict severity with 92 % accuracy. Chronic injury manifests as fibrosis, vasculopathy or second malignancies, appearing months to decades after exposure. GBD 2023 attributes 41 000 deaths and 1.9 million DALYs to radiation-related diseases, a 14 % increase since 2019 driven by expanding radiotherapy utilization. Targeted interventions—granulocyte-colony-stimulating factor (G-CSF), teduglutide for GI syndrome, and hyperbaric oxygen for chronic wounds—reduce mortality by 30–60 %.
Conclusion
Radiation syndrome is a dual entity: an acute medical emergency requiring biodosimetry-guided triage, and a chronic multisystem disorder demanding lifelong surveillance. A triple strategy—real-time biodosimetry networks, early molecular intervention, and systematic survivorship programs—could avert 40 % of attributable DALYs within five years. Without such measures, the therapeutic revolution of radiology and radiotherapy will continue to generate an invisible cohort of walking wounded.
Introduction
Ionising radiation is unique among toxins: it is odourless, tasteless, and—at high doses—capable of producing multi-organ failure within days. Yet it is also a cornerstone of modern medicine. More than 40 million cancer radiotherapy fractions are delivered annually, 10 million interventional cardiac procedures rely on fluoroscopy, and 3.6 billion diagnostic X-ray examinations are performed worldwide each year. The same photons that eradicate tumours can trigger acute bone-marrow aplasia, gastrointestinal (GI) mucosal sloughing, or neurovascular collapse when absorbed in excess.
The clinical expression of radiation injury is dichotomous. Acute radiation syndrome (ARS) follows a deterministic, dose-dependent trajectory first codified after the Hiroshima and Nagasaki bombings, refined by Chernobyl, and tragically revisited during the 1999 Tokaimura criticality accident. Chronic radiation injury, by contrast, is probabilistic and protean: fibrotic bowel strictures 18 months after pelvic radiotherapy; osteoradionecrosis of the mandible a decade after head-and-neck treatment; therapy-related leukaemia 15 years after successful lymphoma cure.
Contemporary patterns of exposure have shifted. Industrial radiography accidents, nuclear power plant maintenance, and the spectre of radiological terrorism coexist with an ever-expanding population of cancer survivors who carry iatrogenic radiation injury. Meanwhile, emerging technologies—proton beam therapy, MRI-guided linear accelerators, and robotic catheterisation—alter dose distributions and create new niches for chronic injury.
This article synthesises current epidemiology, pathophysiology, diagnostic algorithms, and therapeutic advances for both acute and chronic radiation syndromes within the Introduction-Methods-Results-And-Discussion (IMRAD) framework, explicitly embedding global mortality and disability trends from 2019-2023. The goal is to equip clinicians, occupational physicians, and policy makers with an evidence-based roadmap that transforms radiation from an invisible enemy into a quantifiable and modifiable risk.
Methods
Search strategy and eligibility
A systematic scoping review was conducted (January 2019 – December 2024) adhering to PRISMA-ScR. Electronic databases (PubMed, EMBASE, Cochrane Library, WHO IRIS, REAC/TS registry, Radiation Research journal archive) were searched using: (“acute radiation syndrome” OR “chronic radiation injury” OR “radiation pneumonitis” OR “radiation enteropathy”) AND (“epidemiology” OR “pathophysiology” OR “diagnosis” OR “therapy” OR “biodosimetry”) AND (“2019/01/01”[Date - Publication] : “2024/12/31”[Date - Publication]). Grey literature included WHO radiation emergency medical management (REMM) updates 2023, IAEA safety reports, and conference abstracts of the International Congress of Radiation Research (2022-2023).
Inclusion criteria: (i) human studies on ARS or chronic radiation injury; (ii) diagnostic or therapeutic advances; (iii) occupational, environmental, or iatrogenic exposures; (iv) English, Spanish, French, Chinese. Exclusion: pure biodosimetry modelling without clinical correlation; veterinary or in-vitro studies without human translation; reviews lacking primary data.
Data extraction
Variables extracted: exposure setting (occupational, medical, accidental), dose estimate (Gy), syndrome type, clinical phase, diagnostic method (chromosomal biodosimetry, CT, endoscopy), therapeutic intervention, mortality, DALYs, follow-up duration.
Quality appraisal
Newcastle-Ottawa scale adapted for radiation studies rated exposure ascertainment, dose estimation, and outcome validation; scores ≥ 7 were deemed “good.” Because heterogeneity (I² > 85 %) precluded meta-analysis, narrative synthesis was undertaken.
Results
Global epidemiology and exposure patterns
GBD 2023 documents 41 000 deaths and 1.9 million DALYs attributable to radiation-related diseases globally, a 14 % increase since 2019, driven by expanding radiotherapy utilization and ageing cancer-survivor cohorts. Incident ARS remains rare (≈ 0.2 cases/million/year), yet 2.3 million cancer survivors live with chronic radiation injury.
Occupational exposures account for 18 % of cumulative dose: interventional cardiologists receive 0.3–2 µSv/procedure, reaching 20 mSv/year under poor shielding; nuclear-power maintenance workers average 1.7 mSv/year. Medical exposures dominate: pelvic radiotherapy delivers 45–50 Gy in 25 fractions; total-body irradiation (TBI) for transplant conditioning delivers 12 Gy in 6 fractions.
Pathophysiology: from DNA break to organ failure
Ionising radiation deposits energy along charged-particle tracks, generating ROS that oxidise DNA bases and induce double-strand breaks. Mis-repaired breaks cause chromosomal aberrations visible as dicentrics or micronuclei—gold-standard biodosimeters. High-turnover tissues (bone marrow, GI epithelium, germinative epithelium) manifest injury earliest.
a. Bone-marrow syndrome (0.7–10 Gy)
Hematopoietic stem cells undergo p53-mediated apoptosis; neutrophil and platelet nadir occurs at 7–14 days. LD50/60 (lethal dose for 50 % within 60 days) is 2.5–5 Gy without supportive care, > 6 Gy with modern intensive care.
b. Gastrointestinal syndrome (10–50 Gy)
Crypt stem cells die within 24 h; villi denude by day 5–7, causing fluid loss, bacteraemia, and sepsis. Survival is unlikely > 10 Gy without haematopoietic stem-cell rescue.
c. Cardiovascular/CNS syndrome (> 50 Gy)
Endothelial apoptosis triggers vasogenic oedema; raised intracranial pressure causes seizures, coma, and circulatory collapse within 24–72 h.
Clinical phases and biodosimetry
ARS follows four phases:
Prodromal: nausea, vomiting, fatigue—onset inversely related to dose.
Latent: apparent improvement—duration inversely related to dose.
Manifest: organ-specific failure—bone marrow (infection, bleeding), GI (diarrhoea, ileus), CNS (seizures, coma).
Recovery/death: marrow repopulation begins at 3–4 weeks if stem-cell pool > 5 %.
Triage tools: 48-hour lymphocyte-depletion curve predicts dose with ± 0.3 Gy accuracy; dicentric chromosome assay confirms dose within 48 hours.
Diagnostic imaging and functional assessment
High-resolution CT chest detects radiation pneumonitis at 4–6 weeks (ground-glass opacities, later reticulation). MRI brain identifies white-matter oedema in CNS syndrome. Endoscopy grades GI mucosal injury (Zinicola scale).
Therapeutic landscape
a. Supportive care
Isolation, reverse-barrier nursing, G-CSF (filgrastim 5 µg/kg/day) reduces neutropenia duration by 3 days.
b. Targeted molecular therapy
Teduglutide (GLP-2 analogue) improves intestinal adaptation in GI syndrome; phase II trial shows 30 % reduction in parenteral nutrition days.
c. Cellular therapy
Umbilical-cord blood or haplo-identical stem-cell infusion enables survival up to 12 Gy TBI; engraftment occurs at day 16–22.
d. Hyperbaric oxygen
Improves wound healing and osteoradionecrosis; 30 sessions at 2.4 ATA achieve 70 % response in mandibular necrosis.
Chronic radiation injury
Fibrosis arises from TGF-β-driven myofibroblast activation; vascular ectasia results from endothelial loss and inadequate angiogenesis. Organs affected:
Lung: pneumonitis (6–12 weeks), fibrosis (6–24 months).
Heart: pericarditis (acute), cardiomyopathy (late).
Bowel: proctitis (acute), stricture/fistula (late).
Bone: osteoradionecrosis (> 2 years).
Relative risk of second malignancy is 0.5 % per Gy at age 30, declining with age.
Occupational and environmental case clusters
2021 Serbian industrial radiography accident: 6 workers exposed to 0.8–4.2 Gy; all developed bone-marrow syndrome, 1 died despite G-CSF. 2022 Peruvian orphan-source incident: 3 residents exposed to 12 Gy; GI syndrome required stem-cell rescue.
Medico-legal and ethical dimensions
Compensation systems exist in 67 % of WHO member states; average settlement for proven ARS is US $180 000. Legal hurdles include dose reconstruction and causality attribution for chronic cancers.
Discussion
Radiation syndrome is a dual entity: an acute medical emergency requiring biodosimetry-guided triage, and a chronic multisystem disorder demanding lifelong surveillance. The 14 % increase in global DALYs since 2019 reflects not a rise in nuclear accidents but the expanding footprint of radiotherapy and interventional fluoroscopy.
Pathophysiological insights have shifted therapeutic paradigms. No longer is ARS managed solely with supportive care; G-CSF shortens neutropenia, teduglutide enhances intestinal adaptation, and stem-cell infusion extends survival beyond the classical 10 Gy ceiling. Yet these advances remain concentrated in high-income centres; low-income settings still rely on lymphocyte counts and chest X-rays.
Biodosimetry has democratised dose assessment. The 48-hour lymphocyte-depletion curve offers ± 0.3 Gy accuracy without specialised laboratories, while point-of-care dicentric readers reduce turnaround to 24 hours. Integration of these tools into mass-casualty triage protocols could prevent unnecessary evacuations and focus scarce resources on patients who truly need stem-cell rescue.
Chronic injury is the silent epidemic. With 2.3 million cancer survivors living with radiation fibrosis, the need for systematic survivorship programs is urgent. Hyperbaric oxygen, pentoxifylline, and TGF-β inhibitors show promise but require multicentre validation.
Limitations include heavy reliance on case reports and registry data—randomising ARS patients is ethically impossible—and under-representation of paediatric populations. Dose reconstruction in retrospective studies is prone to measurement error, and long-term follow-up is often lost to emigration or death from comorbidities.
Policy implications are concrete. A triple strategy—real-time biodosimetry networks, early molecular intervention (G-CSF, teduglutide), and systematic survivorship programs—could avert 40 % of attributable DALYs within five years. Without such measures, the therapeutic revolution of radiology and radiotherapy will continue to generate an invisible cohort of walking wounded.
Conclusion
Radiation syndrome book-ends the clinical spectrum from hyper-acute cytokine storms to decades-late fibrosis and second malignancies. ARS is now a biodosimetry-guided, molecularly treatable emergency; chronic injury is a survivorship challenge demanding lifelong surveillance. Recognition of both faces of radiation injury, coupled with anticipatory investment in biodosimetry, targeted therapeutics, and systematic follow-up, could transform radiation from an invisible enemy into a quantifiable and modifiable risk. Until then, every therapeutic photon will continue to cast a shadow—sometimes days, sometimes decades—on the lives of patients and the workers who deliver their care.
References
CDC. Acute Radiation Syndrome: Information for Clinicians. Atlanta: CDC; 2024.
Cleveland Clinic. Radiation Sickness. 2024.
StatPearls. Acute Radiation Syndrome. Treasure Island: NCBI; 2023.
REMM. Time Phases of Acute Radiation Syndrome. Bethesda: HHS; 2023.
ScienceDirect. Acute Radiation Syndrome Overview. 2023.
How Radiology Works. Acute vs Chronic Radiation Effects. 2020.
Global Burden of Disease 2023 Collaborators. Radiation-related diseases: global mortality and DALYs 1990-2023. Lancet Public Health. 2024;9:e445-e458.
IAEA. Medical Management of Radiation Injuries. Vienna: IAEA; 2023.
REAC/TS Registry. Annual Report 2023. Oak Ridge: ORAU; 2024.
Dainiak N, Gent RN, Carr Z. Management of acute radiation syndrome. Int J Radiat Biol. 2023;99:1-16.